Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease
Panpan Zhou,Ge Song,Wan-Ting He,Nathan Beutler,Longping V Tse,David R Martinez,Alexandra Schäfer,Fabio Anzanello,Peter Yong,Linghang Peng,Katharina Dueker,Rami Musharrafieh,Sean Callaghan,Tazio Capozzola,Meng Yuan,Hejun Liu,Oliver Limbo,Mara Parren,Elijah Garcia,Stephen A Rawlings,Davey M Smith,David Nemazee,Joseph G Jardine,Ian A Wilson,Yana Safonova,Thomas F Rogers,Ralph S Baric,Lisa E Gralinski,Dennis R Burton,Raiees Andrabi,Wan-ting He,Longping V. Tse,David R. Martinez,Stephen A. Rawlings,Davey M. Smith,Joseph G. Jardine,Ian A. Wilson,Thomas F. Rogers,Ralph S. Baric,Lisa E. Gralinski,Dennis R. Burton
DOI: https://doi.org/10.1101/2022.03.04.479488
2022-03-07
Abstract:Abstract Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against coronaviruses that cause severe disease, for anticipating novel pandemic-causing viruses, and to respond more effectively to SARS-CoV-2 variants. The emergence of the Omicron variant of SARS-CoV-2 has illustrated the limitations of solely targeting the receptor binding domain (RBD) of the envelope Spike (S)-protein. Here, we isolated a large panel of broadly neutralizing antibodies (bnAbs) from SARS-CoV-2 recovered-vaccinated donors that target a conserved S2 region in the fusion machinery on betacoronavirus spikes. Select bnAbs show broad in vivo protection against all three pathogenic betacoronaviruses, SARS-CoV-1, SARS-CoV-2 and MERS-CoV, that have spilled over into humans in the past 20 years to cause severe disease. The bnAbs provide new opportunities for antibody-based interventions and key insights for developing pan-betacoronavirus vaccines.